ClinicalTrials.gg
CompletedNCT05841940Updated Jan 16, 2024

Mass Balance Study of [14C]HLX208 in China Healthy Subjects

A Phase 1 interventional study of [14C]HLX208 in Mass Balance Study in Healthy Subjects, sponsored by Shanghai Henlius Biotech. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-16.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Mass Balance Study of [14C]HLX208 in China Healthy Subjects.

Read the detailed description

A phase I study to quantify the total mass balance in healthy subjects after a single dose of [14C]HLX208.

02

Conditions studied

  • Mass Balance Study in Healthy Subjects
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects between the ages of 18 and 45 years (inclusive).
  2. Subjects weighing ≥ 50 kg and of 18.0 to 32.0 kg/m2.
  3. No sperm donation or fertility plan during the study and within 12 months after the end of the study.
  4. Subjects who have voluntarily participated in the study and signed the form with good compliance.

Exclusion criteria

Exclusion Criteria:

  1. Known history of drug or food allergy.
  2. Known medical history judged by the investigator as not suitable for the study.
  3. Has laboratory or physical examination abnormalities during the screening period.
  4. Has a positive test for, ,,,or syphilis.
  5. Has drug abuse history or positive drug abuse test results.
  6. Has diseases affecting the absorption, distribution, metabolism, and excretion of oral drugs.
  7. Has any other conditions judged by the investigator as not suitable for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]HLX208

    Single oral dose of 450mg \[14C\]HLX208 suspension.

    Drug: [14C]HLX208

Interventions

06

What researchers measure

Primary outcomes

  1. Mass balance recovery of total radioactivity in urine and fecal samples.

    Mass balance recovery of total radioactivity in urine and fecal samples.

    Time frame: Up to 336 hours post dose.

  2. Total radioactivity in plasma PK: Cmax

    Maximum plasma concentration

    Time frame: Up to 240 hours post dose.

  3. Total radioactivity in plasma PK: Tmax

    Time for Cmax

    Time frame: Up to 240 hours post dose.

  4. Total radioactivity in plasma PK: AUC0-t

    Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration.

    Time frame: Up to 240 hours post dose.

  5. Total radioactivity in plasma PK: AUC0-∞

    Area under the plasma concentration time profile from time 0 to infinity.

    Time frame: Up to 240 hours post dose.

  6. Total rradioactivity in plasma PK: t1/2

    Elimination half-life.

    Time frame: Up to 240 hours post dose.

  7. Total radioactivity in plasma PK: CL/F

    Drug clearance.

    Time frame: Up to 240 hours post dose.

  8. Total radioactivity in plasma PK: Vz/F

    Apparent volume of distribution following oral administration.

    Time frame: Up to 240 hours post dose.

Secondary outcomes

  1. HLX208 and metabolite PK: Cmax

    Maximum plasma concentration

    Time frame: Up to 240 hours post dose.

  2. HLX208 and metabolite PK: Tmax

    Time for Cmax

    Time frame: Up to 240 hours post dose.

  3. HLX208 and metabolite PK: AUC0-t

    Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration.

    Time frame: Up to 240 hours post dose.

  4. HLX208 and metabolite PK: AUC0-∞

    Area under the plasma concentration time profile from time 0 to infinity.

    Time frame: Up to 240 hours post dose.

  5. HLX208 and metabolite PK: t1/2

    Elimination half-life.

    Time frame: Up to 240 hours post dose.

  6. Adverse events

    Number of adverse events, which are any untoward medical occurrence regardless of attribution to study drug in a participant who received study drug.

    Time frame: Screening up to Day 15

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 3, 2023
StartActual
Jun 17, 2023
Primary completionActual
Jul 15, 2023
CompletionActual
Dec 15, 2023
Last update
Jan 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05841940
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Jun 17, 2023
Primary completion
Jul 15, 2023
Completion
Dec 15, 2023
Last update
Jan 16, 2024

Study contacts

Liyan Miao, Dr.
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BRAF V600E Inhibitor HLX208

Start the discussion